Drug labeling and exposure in neonates

scientific article published on February 2014

Drug labeling and exposure in neonates is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1001/JAMAPEDIATRICS.2013.4208
P932PMC publication ID3927948
P698PubMed publication ID24322269

P50authorReese H ClarkQ39492406
Michael Cohen-WolkowiezQ93049830
P2093author name stringP Brian Smith
Christoph P Hornik
Matthew M Laughon
Debbie Avant
Nidhi Tripathi
William Rodriguez
P2860cites workInnovative clinical trial design for pediatric therapeuticsQ24635308
Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmiaQ31805892
Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmiaQ32157061
Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.Q33705707
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonatesQ33983697
Metoclopramide, H2 blockers, and proton pump inhibitors: pharmacotherapy for gastroesophageal reflux in neonatesQ34030734
Developmental pharmacology--drug disposition, action, and therapy in infants and childrenQ34247047
Inhaled nitric oxide in preterm infants undergoing mechanical ventilationQ34551446
Early inhaled nitric oxide therapy in premature newborns with respiratory failureQ34551453
Unlicensed and off-label drug use in an Australian neonatal intensive care unitQ34988031
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacyQ35222977
Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitisQ36300569
Changing patterns of drug utilization in a neonatal intensive care populationQ36519127
NIH consensus development conference: Inhaled nitric oxide therapy for premature infantsQ37806069
Early dexamethasone therapy in preterm infants: a follow-up studyQ42542989
A trial of three antiretroviral regimens in HIV-1-infected childrenQ42629119
HES 130/0.4 (Voluven) or human albumin in children younger than 2 yr undergoing non-cardiac surgery. A prospective, randomized, open label, multicentre trialQ42648259
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus diseaseQ42696550
Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).Q43122470
The safety and efficacy of sevoflurane anesthesia in infants and children with congenital heart diseaseQ43589027
Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hoursQ43673455
A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. I. Emergence and recovery profilesQ43810968
A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. II. Perioperative breathing patterns in neonates and infants with pyloric stenosisQ43810972
Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmiaQ43985373
Famotidine for infant gastro‐oesophageal reflux: a multi‐centre, randomized, placebo‐controlled, withdrawal trialQ44444407
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in childrenQ44546116
Impact of ontogeny on linezolid disposition in neonates and infantsQ44637316
Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of lifeQ44960395
Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trialQ45025783
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspringQ45753331
Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease.Q46037136
THE EFFECTS OF TETRACYCLINES UPON THE DENTITION.Q46288999
Age-dependent pharmacokinetics of lansoprazole in neonates and infantsQ46510339
Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 yearQ46510346
Changing pattern of drug utilization in a neonatal intensive care unitQ71225017
[The incidence of prescriptions without marketing product license in a neonatal intensive care unit]Q73507020
Pharmacokinetics and pharmacodynamics of famotidine in infantsQ73746962
A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimensQ74267298
Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenationQ74592727
A survey of the use of off-label and unlicensed drugs in a Dutch children's hospitalQ77123451
Fatal circulatory collapse in premature infants receiving chloramphenicolQ79179771
Pediatric information in drug product labelingQ84092390
P433issue2
P407language of work or nameEnglishQ1860
P304page(s)130-136
P577publication date2014-02-01
P1433published inJAMA PediatricsQ4787306
P1476titleDrug labeling and exposure in neonates
P478volume168

Reverse relations

cites work (P2860)
Q38480753A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development
Q54194778Advances in Pediatric Pharmacology, Therapeutics, and Toxicology.
Q33998667Advances in pediatric pharmacology, therapeutics, and toxicology
Q39147483Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants
Q42019687An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children
Q28088630Anesthetic use in newborn infants: the urgent need for rigorous evaluation
Q90298395Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition
Q88816139Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia
Q90178818Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research
Q36887756Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants
Q47917646Collaboration in Regulatory Science to Facilitate Therapeutic Development for Neonates
Q34458246Comparative effectiveness of digoxin and propranolol for supraventricular tachycardia in infants
Q38649419Dosing antibiotics in neonates: review of the pharmacokinetic data
Q34716879Dosing in neonates: special considerations in physiology and trial design
Q36776390Drug-induced acute kidney injury in neonates
Q26849339Drug-induced renal damage in preterm neonates: state of the art and methods for early detection
Q38263730Ethics of drug studies in the newborn.
Q38965300How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.
Q90208079International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States
Q54240649Large differences in neonatal drug use between NICUs are common practice: time for consensus?
Q57156418Maternal and environmental risk factors for neonatal AKI and its long-term consequences
Q36652800Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks
Q47304205Methodological and Ethical Issues in Pediatric Medication Safety Research
Q38626545Neonatal Safety Information Reported to the FDA During Drug Development Studies
Q26780200Neonatal anesthesia: how we manage our most vulnerable patients
Q38469763Neonatal medicines research: challenges and opportunities
Q53798658Newborns still lack drug data to guide therapy.
Q40405030Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study
Q38215682Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.
Q38696468Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates
Q48076685Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants
Q94544639Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables
Q30938796Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling
Q47428031Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates
Q34628384Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons
Q90726651Surfactant Administration in Preterm Infants: Drug Development Opportunities
Q38222870Tailored tools to improve pharmacotherapy in infants
Q87434784The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans
Q38265444The principle of equipoise in pediatric drug trials.
Q92206554Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union

Search more.